Technology
Health
Biotechnology

FibroGen

$35.89
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.44 (1.25%) Today
+$0.31 (0.89%) After Hours

Why Robinhood?

You can buy or sell FibroGen and other stocks, options, ETFs, and crypto commission-free!

About

FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Read More The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Employees
461
Headquarters
San Francisco, California
Founded
1993
Market Cap
3.06B
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
636.09K
High Today
$35.88
Low Today
$35.31
Open Price
$35.50
Volume
291.54K
52 Week High
$68.55
52 Week Low
$33.51

Collections

Technology
Health
Biotechnology
Therapy
Cancer Prevention
2014 IPO
US
North America

News

Seeking AlphaMay 22

FibroGen's Roxadustat Shows A Clear Positive Phase III MACE Result, But Future Sales Remain Uncertain

FibroGen's (NASDAQ:FGEN) stock price has experienced a rocky ride in the past month. During the after hour on May.9th, it dropped more than 20% after the announcement of its Roxadustat's seven Phase III result with pooled MACE (Major Adverse Cardiovascular Events) analysis for US and MACE+ (MACE with plus hospitalization due to heart failure or unstable angina) for EU. However, the market seems to be confused by this outcome. Before jumping into the result, let's first understand how important MACE/MACE+ o...

57
Yahoo FinanceMay 9

FibroGen Reports Q1 Loss, Tops Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of 22.06% and 19.32%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

191
Seeking AlphaMay 9

Akebia feels FibroGen's roxadustat pain, down 7%

Akebia Therapeutics (NASDAQ:AKBA) is down 7% after hours on average volume in apparent sympathy with the selloff in FibroGen after it announced disappointing safety data on roxadustat.

116

Earnings

-$0.67
-$0.37
-$0.07
$0.23
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
β€”
Actual
Expected Aug 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.